The historical rank and industry rank for Cartesian Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
During the past 10 years, Cartesian Therapeutics's highest Price to Tangible Book Ratio was 24.47. The lowest was 1.84. And the median was 5.75.
RNAC's Price-to-Tangible-Book is not ranked *
in the Biotechnology industry.
Industry Median: 2.71 * Ranked among companies with meaningful Price-to-Tangible-Book only.
Cartesian Therapeutics Price-to-Tangible-Book Historical Data
The historical data trend for Cartesian Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cartesian Therapeutics's Price-to-Tangible-Book
For the Biotechnology subindustry, Cartesian Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cartesian Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Cartesian Therapeutics's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Cartesian Therapeutics Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Cartesian Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Cartesian Therapeutics (Cartesian Therapeutics) Business Description
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RNAC has been successfully added to your 